Similar articles

• ASCOT-LLA: questions about the benefits of atorvastatin.

  Devroey D, Ginst LV. Devroey D, et al. Lancet. 2003 Jun 7;361(9373):1985-6; author reply 1986-7. doi: 10.1016/s0140-6736(03)13558-1. Lancet. 2003. PMID: 12801760 No abstract available.
• ASCOT-LLA: questions about the benefits of atorvastatin.

  Ravnskov U. Ravnskov U. Lancet. 2003 Jun 7;361(9373):1986; author reply 1986-7. doi: 10.1016/S0140-6736(03)13559-3. Lancet. 2003. PMID: 12801761 No abstract available.
• The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

  Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes G, Mehlsen J, Nieminen MS, O'Brien ET, Ostergren J; ASCOT Investigators. Sever PS, et al. Eur Heart J. 2008 Feb;29(4):499-508. doi: 10.1093/eurheartj/ehm583. Epub 2008 Jan 5. Eur Heart J. 2008. PMID: 18175773 Clinical Trial.
• Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.

  Osende JI, Ruiz-Ortega M, Blanco-Colio LM, Egido J. Osende JI, et al. Nephrol Dial Transplant. 2004 Mar;19(3):528-31. doi: 10.1093/ndt/gfg538. Nephrol Dial Transplant. 2004. PMID: 14767002 Review. No abstract available.
• [AVERT [The Atorvastatin versus Revascularization Treatment]].

  Mokuno H. Mokuno H. Nihon Rinsho. 2001 Mar;59 Suppl 3:436-41. Nihon Rinsho. 2001. PMID: 11347110 Review. Japanese. No abstract available.